WHY THE PHARMACEUTICAL INDUSTRY IS ADOPTING PERSONALIZED MEDICINE NOW ? Presented by Jean-Claude MULLER – Special Advisor At the 1st Translational Medicine Summit, Dalian, China, June 27-30, 2014     Download the pdf to view the powerpoint presentation • Healthcare costs in the US • Prescription Drug Costs • The current healthcare model • The […]

1.Polical & Economical background 2.Why going on the Chinese market for SME 3.Priority areas 4.What we should know about china ? 5.Healthcare is the priority of the Chinese government 6.Few exemples of French SME that decided to go on the Chinese Market 7.Conclusion (news available only in french, Verbatim of Jean-Claude Muller talk at “China: which […]

1st Annual Translational Medicine Partnership Summit, in Dalian (China), June 27-29, 2014     Dr. Jean-Claude Muller, Special Advisor at I&IR, will be presenting at the 1st Annual Translational Medicine Partnership Summit, in Dalian (China), a conference entitled “Why the pharmaceutical industry is adopting personalized medicine now”. The slides will be posted on the btobioinnovation site […]

China: which assets & tools for French SME  On June 13, in La Rochelle (France), Dr. Jean-Claude Muller, will be part of the meeting, dedicated to the role small and medium companies could have on the development of China. He will specifically talk on “The New Chinese Markets: A huge opportunity for French small companies”. […]

Biopharmaceutical NewsWeek # 5   Acquisitions /Mergers/Joint-ventures May 26, 2014 As expected Pfizer has abandoned its desire to acquire AstraZeneca for $116B saying that “it does not intend to make an offer” fort the Bristish-Swedish company after the board rejected its latest offer. Under British law Pfizer cannot make another bid for AstraZeneca for three-to-six […]